GLG Network Survey Tracker: Generics Market Overview III

SURVEY DETAILS

TARGET POPULATION

GLG surveyed surveyed 70 senior executives working in the pharmaceutical industry across the US and Europe (UK, France, Germany, Italy and Spain). This is the third iteration in this tracker series.

What will you learn from this survey?

• Respondents provided their views on the current trends for different key products and discussed the impact of COVID-19 on R&D, manufacturing, supply chain and marketing, as well as development in their key markets and therapeutic areas post-COVID-19.
• The survey also investigated the anticipated level of interest in generics from manufacturers, impact of price control measures and important drivers of generics industry.
• Lastly, the research looked at concerns from in-house development and manufacturing vs CDMO partners in terms of reliability, quality and delivery as well as inventory issues faced by the industry.

Example of findings:

• Atorvastatin, Metformin and Ibuprofen are among the most produced products (33%, 26% and 21%).
• One-in-five (20%) say it is likely to have quality complaints from in-house development.
• Over two-in-five (45%) have seen a negative impact due to price control measures, only one-third (33%) say it has been slightly positive.

DELIVERABLES

The GLG Surveys team drafted the questionnaire with the support of GLG Network Member, Rainer Wulf, former Director Corporate Development, Branded Products at STADA.

The standard deliverable includes:

• 1 x Individual responses (“raw data”) in Excel.
• 1 x PPT report with aggregated data.
• Executive summary with key takeaways and highlights from the raw data.

SAMPLE QUESTIONS

• How has the COVID-19 pandemic impacted your in-house manufacturing?
• What has been the trend of the post pandemic development of your key therapeutic areas?
• How likely are you to have quality complaints from in-house development and manufacturing?
• In your opinion, how likely are manufacturers to lose interest in generics in the future?
• How would you describe the level of frequency of stock out situations in your organisation?
• In your opinion, what is the level of risk of low availability of APIs/Excipients at acceptable prices, in the future?
• How would you describe the impact of reimbursement and/or funding restrictions in key markets?

ACCESS

This survey is available to subscribers of the Healthcare (HC) sector (Limited subscriptions and above). This offer includes the raw data file and a high-level presentation through PowerPoint. Please contact your GLG representative for details on your firm’s access.

DISCLAIMER:

Please be advised that GLG Network Surveys operate differently than traditional GLG consultations, surveys, teleconferences, etc. and it is advisable that you consult with your firm’s legal and/or compliance department to review your use of the product and the payment for such work under your current subscription. 

By downloading this document and/or participating in the Network Survey, you understand and agree that the information and material provided by GLG, including survey results and survey proposal information, is provided for your own insight and informational purposes only. You further acknowledge and agree that this is a Network Survey for multiple GLG clients, and the results will be provided to all GLG clients that agree to participate in the Network Survey and GLG clients that agree to purchase the Survey results in the future. All survey results do not constitute investment advice or a recommendation. In using this Survey, you agree to hold Gerson Lehrman Group and the Survey respondents harmless and free of all liability as a result of your use of this Network Survey, other than liability resulting from the gross negligence or wilful misconduct of the protected party. You otherwise agree to be bound by Gerson Lehrman Group’s Usage Policies in your interactions with Gerson Lehrman Group and your receipt of services. These Survey results are for are for client’s own use and client shall not redistribute, disseminate, publish, or display the same, in whole or in part, to any third parties or publicly without the prior written permission of Gerson Lehrman Group, except explicitly set forth in your agreement with GLG. This survey will be double-blinded to both client and respondent. GLG reserves the right to restrict the number of clients that can pre-commit access. These Network Surveys are priced outside of standard GLG subscriptions but at a substantially reduced price to commissioning a fully proprietary GLG Network Survey. Upon finding these terms acceptable, please send an affirmative confirmation via email, which GLG will file in its records. Once confirmed, please note that the Client’s agreement to purchase the Network Survey is a legally binding and irrevocable commitment. If the survey is not included within your subscription, GLG will invoice Client for the fees due for the Network Survey. Please note that some respondents may not be Network Members, and the Terms and Conditions of Network Membership would not apply to such respondents and detailed records for them will not be available aside from the information that GLG capture in the Network Survey.